Resistance to HIF-2α inhibitors such as belzutifan underscores the need to better understand how HIF-2α is transcriptionally regulated in clear cell renal cell carcinoma (ccRCC). This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.